🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: 10 mg BI 1356 BS

Found 16 matching trials

Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes

PHASE2

The objective of the study is to test the efficacy, safety and tolerability...

Status

Completed

Location

1218.6.3302A Boehringer Ingelheim Investigational Site

Start Date

2006-04

Trial ID

NCT00309608

Treatments Being Tested

Linagliptin Linagliptin Linagliptin Placebo Glimepiride

Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug

PHASE3

Efficacy and safety of BI 1356 compared to placebo in patients with type 2 ...

Status

Completed

Location

1218.35.10002 Boehringer Ingelheim Investigational Site

Start Date

2008-12

Trial ID

NCT00819091

Treatments Being Tested

BI 1356 Placebo

Bioavailability of BI 1356 BS and Metformin After Co-administration Compared to the Bioavailability of BI 1356 BS Alone and Metformin Alone in Healthy Male Volunteers

PHASE1

Investigate the bioavailability of BI 1356 BS and of metformin after concom...

Status

Completed

Location

Multiple Locations

Start Date

2005-09

Trial ID

NCT02183506

Treatments Being Tested

Metformin BI 1356 BS

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

PHASE3

The objective of the study is to investigate the efficacy, safety and toler...

Status

Completed

Location

1275.10.01019 Boehringer Ingelheim Investigational Site

Start Date

2013-01

Trial ID

NCT01778049

Treatments Being Tested

BI 10773 BI 10773 Placebo BI 10773 / BI 1356 BI 10773 BI 10773 / BI 1356 BI 10773 / BI 1356 Placebo BI 10773 BI 10773 BI 10773 BI 10773 / BI 1356 Placebo BI 10773 Placebo BI 10773 / BI 1356 Placebo BI 10773 BI 10773 / BI 1356 Placebo

Bioavailability of Warfarin After Coadministration With Multiple Doses of BI 1356 Compared to the Bioavailability of Warfarin Alone in Healthy Male Volunteers

PHASE1

To investigate whether and to what extent BI 1356 affects pharmacokinetic a...

Status

Completed

Location

Multiple Locations

Start Date

2008-05

Trial ID

NCT02183389

Treatments Being Tested

Warfarin BI 1356

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes

PHASE1

Study to investigate the safety, tolerability, pharmacokinetics, and pharma...

Status

Completed

Location

Multiple Locations

Start Date

2005-08

Trial ID

NCT02183415

Treatments Being Tested

BI 1356 BS, low dose BI 1356 BS, medium dose BI 1356 BS, high dose Placebo

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

PHASE3

This trial will evaluate use of BI 10773/linagliptin once daily (qd) fixed ...

Status

Completed

Location

1275.1.01103 Boehringer Ingelheim Investigational Site

Start Date

2011-08

Trial ID

NCT01422876

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male Volunteers

PHASE1

Study to examine the safety, tolerability, pharmacokinetics, and pharmacody...

Status

Completed

Location

Multiple Locations

Start Date

2006-06

Trial ID

NCT02183311

Treatments Being Tested

BI 1356 BS - single rising dose BI 1356 BS - multiple rising dose Placebo

BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus

PHASE2

Study to evaluate the safety, tolerability, pharmacokinetics, and pharmacod...

Status

Completed

Location

Multiple Locations

Start Date

2007-02

Trial ID

NCT02183324

Treatments Being Tested

Low dose of BI 1356 BS Medium dose of BI 1356 BS High dose of BI 1356 BS Placebo

The Effect of Multiple Oral Doses of BI 1356 BS on Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of Simvastatin and on the Pharmacokinetics of Its Metabolite Simvastatin Acid in Healthy Male Volunteers

PHASE1

Investigation of the multiple dose pharmacokinetics, safety and tolerabilit...

Status

Completed

Location

Multiple Locations

Start Date

2005-09

Trial ID

NCT02183623

Treatments Being Tested

Simvastatin 10 mg BI 1356 BS

Previous Next